Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology

06-09-2024 | Esophageal Cancer | Thoracic Oncology

ANGPTL2: Is it a Novel Therapeutic Target Related to Tumor-Associated Macrophages in Esophageal Cancer?

Author: Masayuki Watanabe, MD, PhD, FACS

Published in: Annals of Surgical Oncology

Login to get access

Excerpt

Recent studies elucidated that tumor microenvironment (TME) influences tumor biology, including proliferation, invasion, and migration, and thus affects patients’ outcomes.1 Tumor-associated macrophage (TAM) is a critical player of TME, consisting of two distinct phenotypes, M1- and M2-types.2 These two types of TAMs play opposite roles in tumor progression: M1-type is known to inhibit tumor progression, whereas M2-type promotes tumor growth and aids in tumor immune evasion. M2-type macrophages are the predominant subtype of TAMs in esophageal squamous cell carcinoma (ESCC) and are associated with poorer overall survival.3 …
Literature
1.
2.
3.
Yagi T, Baba Y, Okadome K, et al. Tumour-associated macrophages are associated with poor prognosis and programmed death ligand 1 expression in oesophageal cancer. Eur J Cancer. 2019;111:39–49.CrossRef
4.
Tabata M, Kadomatsu T, Fukuhara S, et al. Angiopoietin-like protein 2 promotes chronic adipose tissue inflammation and obesity-related systemic insulin resistance. Cell Metab. 2009;10:178–88.CrossRefPubMed
5.
Endo M, Nakano M, Kadomatsu T, et al. Tumor cell-derived angiopoietin-like protein ANGPTL2 is a critical driver of metastasis. Cancer Res. 2012;72:1784–94.CrossRefPubMed
6.
7.
Villar VH, Subotički T, Ðikić D, et al. Transforming growth factor-β1 in cancer immunity: opportunities for immunotherapy. Adv Exp Med Biol. 2023;1408:309–28.CrossRefPubMed
8.
Derynck R, Turley SJ, Akhurst RJ. TGF-β biology in cancer progression and tumor immunotherapy. Nat Rev Clin Oncol. 2021;18:9–34.CrossRefPubMed
9.
Sawada G, Niida A, Uchi R, et al. Genomic landscape of esophageal squamous cell carcinoma in a Japanese population. Gastroenterology. 2016;150:1171–82.CrossRefPubMed
10.
Baba Y, Nomoto D, Okadome K, et al. Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma. Cancer Sci. 2020;111:3132–41.CrossRefPubMedPubMedCentral
11.
Metadata
Title
ANGPTL2: Is it a Novel Therapeutic Target Related to Tumor-Associated Macrophages in Esophageal Cancer?
Author
Masayuki Watanabe, MD, PhD, FACS
Publication date
06-09-2024
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-024-16135-6
SPONSORED

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

  • Webinar | 06-02-2024 | 20:00 (CET)

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by:
  • Viatris
Developed by: Springer Healthcare
Watch now
Image Credits